Healthcare · Pharmaceuticals & Biotechnology
Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.
Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.
PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.
Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.
Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.
Data unavailable (needs at least 2 historical quarters with both a filed EPS and a matching trading day).
Ranks #50 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.
| Date | Client | Deal | Action | Quantity | Price | Exchange |
|---|---|---|---|---|---|---|
| 2 Sep 2026 | JUNOMONETA FINSOL PRIVATE LIMITED | Bulk | Buy | 357,516 | 1123.4000 | NSE |
| 2 Sep 2026 | JUNOMONETA FINSOL PRIVATE LIMITED | Bulk | Sell | 357,516 | 1123.6800 | NSE |
| 1 Sep 2026 | YUGA STOCKS AND COMMODITIES PRIVATE LIMITED | Bulk | Sell | 446,917 | 1057.6300 | NSE |
| 1 Sep 2026 | YUGA STOCKS AND COMMODITIES PRIVATE LIMITED | Bulk | Buy | 471,917 | 1051.4600 | NSE |
| 1 Sep 2026 | TIMF HOLDINGS | Bulk | Buy | 377,247 | 989.2000 | NSE |
| 1 Sep 2026 | PURE BROKING PRIVATE LIMITED | Bulk | Sell | 627,323 | 1049.4400 | NSE |
| 1 Sep 2026 | PURE BROKING PRIVATE LIMITED | Bulk | Buy | 628,198 | 1049.0100 | NSE |
| 1 Sep 2026 | NK SECURITIES RESEARCH PRIVATE LIMITED | Bulk | Sell | 842,160 | 1063.8800 | NSE |
| 1 Sep 2026 | NK SECURITIES RESEARCH PRIVATE LIMITED | Bulk | Buy | 842,160 | 1063.4200 | NSE |
| 1 Sep 2026 | MICROCURVES TRADING PRIVATE LIMITED | Bulk | Buy | 667,966 | 1104.2900 | NSE |
Quarterly results, AGMs, buybacks and other board-approved business.
| Date | Purpose | Results |
|---|---|---|
| 21 Sep 2026 | Financial Results | Yes |
Exchange disclosures (NSE and BSE), most recent first.
| Date | Category | Announcement |
|---|---|---|
| 30 Sep 2026 | Company Update | Symbiotec Pharmalab Ltd - 544889 - Symbiotec''s Wholly Owned Subsidiary Knovea Pharmaceutical Enters Into Strategic Commercialization Agreement With A Leading Global Pharmaceutical Company For Dual Chamber Vial Products In The U.S. |
| 30 Sep 2026 | General Updates | Symbiotec's wholly owned subsidiary Knovea Pharmaceutical enters into strategiccommercialization agreement with a leading global pharmaceutical company forDual Chamber Vial ('DCV') products in the U.S. |
| 30 Sep 2026 | General Updates | Symbiotec Pharmalab Limited has informed the Exchange about General Updates |
| 29 Sep 2026 | Trading Window | Symbiotec Pharmalab Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 |
| 29 Sep 2026 | General Updates | Announcement Under Regulation 30 (LODR)-Symbiotec Pharmalab Limited Receives Establishment Inspection Report ("EIR") From U.S. FDA for Its Manufacturing Facility In Pithampur ('SEZ') With VAI Classification |
| 29 Sep 2026 | Insider Trading / SAST | Symbiotec Pharmalab Ltd - 544889 - Closure of Trading Window |
| 29 Sep 2026 | Company Update | Symbiotec Pharmalab Ltd - 544889 - Announcement Under Regulation 30 (LODR)-Symbiotec Pharmalab Limited Receives Establishment Inspection Report ("EIR") From U.S. FDA For Its Manufacturing Facility In Pithampur ('SEZ') With VAI Classification |
| 28 Sep 2026 | Analysts/Institutional Investor Meet/Con. Call Updates | Symbiotec Pharmalab Limited has informed the Exchange about Transcript |
| 28 Sep 2026 | Company Update | Symbiotec Pharmalab Ltd - 544889 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript |
| 22 Sep 2026 | Analysts/Institutional Investor Meet/Con. Call Updates | Symbiotec Pharmalab Limited has informed the Exchange about Link of Recording |
Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.
Data unavailable.
Data unavailable.
Data unavailable.
Data unavailable.
Board of directors and corporate information →
Data unavailable (no single-stock futures or options activity on record for this company).
The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.
The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.
The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.
No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.
